Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


As Ranbaxy’s Regulatory Woes Persist, Imitrex Exclusivity Threatened

This article was originally published in The Pink Sheet Daily

Executive Summary

No end in sight for FDA’s import ban on drugs manufactured in Ranbaxy’s Dewas, Paonta Sahib facilities; impact on sales will be felt in 2009.

You may also be interested in...

Ranbaxy May Face Third-Party Oversight Of Ganciclovir Manufacturing

Ranbaxy may be subject to third-party supervision of its manufacturing of the antiviral ganciclovir, in return for gaining an exception for the product from FDA's Import Alert

Daiichi Sankyo Ranbaxy Acquisition Very Much Alive

Details of tender offer at 40 percent premium revealed.

Why Is Congress Targeting These Six Medicines In Drug Price Hearing?

Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts